Biology-driven therapy advances in high-grade serous ovarian cancer

Y Wang, AJ Duval, M Adli, D Matei - The Journal of Clinical Investigation, 2024‏ - jci.org
Following a period of slow progress, the completion of genome sequencing and the
paradigm shift relative to the cell of origin for high grade serous ovarian cancer (HGSOC) led …

Development of PARP and immune-checkpoint inhibitor combinations

RA Stewart, PG Pilié, TA Yap - Cancer research, 2018‏ - aacrjournals.org
PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in
DNA repair. This damage not only promotes immune priming through a range of molecular …

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

S Jiao, W **a, H Yamaguchi, Y Wei… - Clinical Cancer …, 2017‏ - aacrjournals.org
Purpose: To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1
immune checkpoint axis, and determine whether blockade of PD-L1/PD-1 potentiates PARP …

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells

SA Yazinski, V Comaills, R Buisson… - Genes & …, 2017‏ - genesdev.cshlp.org
Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis) selectively kill BRCA1/2-deficient
cells, but their efficacy in BRCA-deficient patients is limited by drug resistance. Here, we …

Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma

S Zhang, I Dolgalev, T Zhang, H Ran, DA Levine… - Nature …, 2019‏ - nature.com
The cell-of-origin of high grade serous ovarian carcinoma (HGSOC) remains controversial,
with fallopian tube epithelium (FTE) and ovarian surface epithelium (OSE) both considered …

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

Z Wang, K Sun, Y **ao, B Feng, K Mikule, XY Ma… - Scientific reports, 2019‏ - nature.com
PARP inhibitors have been proven clinically efficacious in platinum-responsive ovarian
cancer regardless of BRCA1/2 status and in breast cancers with germline BRCA1/2 …

Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns

J Guo, H De May, S Franco, A Noureddine… - Nature biomedical …, 2022‏ - nature.com
The production of personalized cancer vaccines made from autologous tumour cells could
benefit from mechanisms that enhance immunogenicity. Here we show that cancer vaccines …

The mammalian ovary from genesis to revelation

MA Edson, AK Nagaraja, MM Matzuk - Endocrine reviews, 2009‏ - academic.oup.com
Two major functions of the mammalian ovary are the production of germ cells (oocytes),
which allow continuation of the species, and the generation of bioactive molecules, primarily …

CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer

T Higuchi, DB Flies, NA Marjon… - Cancer immunology …, 2015‏ - aacrjournals.org
Immune checkpoint blockade has shown significant therapeutic efficacy in melanoma and
other solid tumors, but results in ovarian cancer have been limited. With evidence that tumor …

Triple negative tumours: a critical review

JS Reis‐Filho, ANJ Tutt - Histopathology, 2008‏ - Wiley Online Library
Breast cancer is a heterogeneous disease that encompasses several distinct entities with
remarkably different biological characteristics and clinical behaviour. Currently, breast …